Mapi Pharma to Present Plans for Additional Studies of GA Depot in Multiple Sclerosis and Other Indications and Highlight Latest Results on GA Depot in Relapsing Multiple Sclerosis at the ECTRIMS-ACTRIMS® Meeting in Milan, Italy October 11-13, 2023
October 10, 2023 09:00 ET
|
Mapi Pharma Ltd.
NESS ZIONA, Israel, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting...
Mapi Pharma to Host a Key Opinion Leader Webinar on Glatiramer Acetate Depot
October 12, 2022 10:09 ET
|
Mapi Pharma Ltd.
GA Depot is a Potential Long Acting Injection Solution for Multiple Sclerosis Patients Positive Results from Phase III GA Depot Study in Relapsing MS to be Reviewed Webinar on Wednesday, October 19,...
Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)
September 21, 2022 08:00 ET
|
Mapi Pharma Ltd.
NESS ZIONA, Israel, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting...
Mapi Pharma to Present Late Breaking Poster Presentation on GA Depot for Treating Primary Progressive Forms of Multiple Sclerosis at CMSC 2022 Annual Meeting
May 31, 2022 09:00 ET
|
Mapi Pharma Ltd.
NESS ZIONA, Israel, May 31, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting...
Mapi Pharma to Present Posters on GA Depot for Treating Relapsing Forms of Multiple Sclerosis (MS) and Primary Progressive Forms of Multiple Sclerosis at the American Academy of Neurology (AAN) 2022 Annual Meeting
March 31, 2022 09:00 ET
|
Mapi Pharma Ltd.
NESS ZIONA, Israel, March 31, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting...
Mapi Pharma Receives U.S. Patent Covering Methods of Suppressing or Alleviating Primary or Secondary Progressive Multiple Sclerosis with a Sustained Release Glatiramer Acetate Depot
March 30, 2022 08:00 ET
|
Mapi Pharma Ltd.
NESS ZIONA, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting...
Mapi Pharma Signs Agreement with Gaelan Medical Trade LLC to Exclusively Market and Distribute Mapi Products in UAE
October 21, 2021 08:30 ET
|
Mapi Pharma Ltd.
DUBAI, United Arab Emirates and NESS ZIONA, Israel, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and high value-added generic...
Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Sclerosis (MS) at ECTRIMS 2021
October 11, 2021 08:30 ET
|
Mapi Pharma Ltd.
Results for Glatiramer Acetate (GA) Depot Phase IIa study in patients with primary progressive multiple sclerosis, and novel anti-BMP for remyelination treatment in MS will be presented ECTRIMS 2021...
Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial
December 21, 2020 09:00 ET
|
Mapi Pharma Ltd.
Patient recruitment in Phase III trial has surpassed 60% Trial is expanded to Israel with first clinical site at Tel Aviv Medical Center NESS ZIONA, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Mapi...
Mapi Pharma Announces Commissioning of a Vaccine Production Facility to Support the Supply of COVID-19 Vaccines to Israel and EU Countries
October 07, 2020 07:00 ET
|
Mapi Pharma Ltd.
NESS ZIONA, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late clinical stage biopharmaceutical company, today announced that it will dedicate capacity at its...